AB197357

Anti-FGL1 antibody

(1 Review)

(8 Publications)

Rabbit Polyclonal FGL1 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 8 publications. Immunogen corresponding to Fusion protein corresponding to FGL1, fused to FGL1.

View Alternative Names

HFREP1, FGL1, Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, Liver fibrinogen-related protein 1, HPS, HFREP-1, LFIRE-1

4 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody (AB197357)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody (AB197357)

Immunohistochemical analysis of paraffin-embedded Human liver cancer tissue labeling FGL1 with ab197357 at 1/50 dilution.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody (AB197357)

Immunohistochemical analysis of paraffin-embedded Human liver cancer tissue labeling FGL1 with ab323611 at 1/2000 (0.25 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Positive staining on (image A) human liver cancer, and (image B) ab197357 showed weak staining on human liver cancer.
The image on (A) ab323611 is applied with Anti-FGL1 antibody at 1/2000 dilution and (B) ab197357 is applied with Anti-FGL1 antibody at 1/420 dilution.
The section was incubated with ab323611 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument

Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Supplier Data

Western blot - Anti-FGL1 antibody (AB197357)

Gel : 15%SDS-PAGE.

All lanes:

Western blot - Anti-FGL1 antibody (ab197357) at 1/500 dilution

All lanes:

Human fetal liver tissue lysate at 40 µg

Predicted band size: 36 kDa

true

Exposure time: 2s

Supplier Data

Western blot - Anti-FGL1 antibody (AB197357)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

Negative control : cerebellum (PMID : 11470158)

The molecular weight observed is consistent with what has been described in the literature (PMID : 11004478).

In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602) staining at 1/200000 dilution.

All lanes:

Western blot - Anti-FGL1 antibody [RM1297] (<a href='/en-us/products/primary-antibodies/fgl1-antibody-rm1297-ab323611'>ab323611</a>) at 1/1000 dilution

Lane 1:

Human liver tissue lysate at 20 µg

Lane 2:

Human liver cancer tissue lysate at 20 µg

Lane 3:

Human cerebellum tissue lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Observed band size: 34 kDa,36 kDa

false

Exposure time: 180s

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IHC-P, WB

applications

Immunogen

Fusion protein corresponding to FGL1, fused to FGL1. The exact immunogen used to generate this antibody is proprietary information.

Q08830

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/2000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/200", "IHCP-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

pH: 7.4 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Fibrinogen-like protein 1 (FGL1) also known as Hepassocin plays a significant role in modulating immune responses. FGL1 is a member of the fibrinogen family with a molecular mass of approximately 31 kDa. This protein is widely expressed in the liver and is also found in other tissues like the pancreas and lungs. Its structural homology to fibrinogen suggests potential binding capabilities with similar ligands influencing its mechanical actions in cellular processes.

Biological function summary

FGL1 modulates the immune system and maintains its homeostasis. It functions primarily as a ligand for the immune checkpoint receptor LAG-3. This FGL1-LAG-3 interaction inhibits T-cell activity leading to immune tolerance and helping prevent autoimmunity. FGL1 while not a part of a complex demonstrates significant standalone biological activity by affecting immune responses especially under pathological conditions.

Pathways

FGL1 integrates into the immune regulatory framework. It exerts its effects mainly through the immune checkpoint pathway impacting T-cell regulation. In addition to LAG-3 FGL1 interacts closely with the PD-1/PD-L1 pathway which is also important in checkpoint inhibition and immune evasion mechanisms. These pathways together orchestrate the immune surveillance system and play roles in maintaining immune equilibrium.

FGL1 has received attention in cancer particularly in its role of suppressing anti-tumor immunity. Its interaction with LAG-3 makes it a potential target for cancer immunotherapy as high FGL1 levels correlate with poor prognosis in various cancers. Additionally it has implications in autoimmune diseases where its regulation of T-cell activity prevents excessive immune responses. By modulating LAG-3 activity FGL1 emerges as a therapeutic target of interest in autoimmune conditions presenting new opportunities for managing such disorders.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a ligand of LAG3 (PubMed : 30580966, PubMed : 35761082, PubMed : 40101708). LAG3-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 30580966). Binds LAG3 independently from MHC class II (MHC-II) (PubMed : 30580966, PubMed : 35761082). Secreted by, and promotes growth of, hepatocytes (PubMed : 11470158, PubMed : 19880967).

See full target information FGL1

style

left-column

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 15:19886 PubMed40481127

2025

Silencing FGL1 promotes prostate cancer cell apoptosis and inhibits EMT progression.

Applications

Unspecified application

Species

Unspecified reactive species

Shuaizhi Zhu,Zengshun Kou,Chengcheng Xiao,Lu Wang,Jiaxi Zhu,Yu Zheng,Hai Zhu

BMC cancer 24:557 PubMed38702629

2024

Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1.

Applications

Unspecified application

Species

Unspecified reactive species

Shan Huang,Jiayi Zhang,Pu He,Xinyue Cui,Yuzhu Hou,Wanghui Su,Fang Li

iScience 26:107883 PubMed37752945

2023

Innate mechanism of mucosal barrier erosion in the pathogenesis of acquired colitis.

Applications

Unspecified application

Species

Unspecified reactive species

Won Ho Yang,Peter V Aziz,Douglas M Heithoff,Yeolhoe Kim,Jeong Yeon Ko,Jin Won Cho,Michael J Mahan,Markus Sperandio,Jamey D Marth

Molecular biology reports 49:7911-7919 PubMed35776395

2022

The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Nanni Hua,Anxian Chen,Chen Yang,Hui Dong,Xianglei He,Guoqing Ru,Xiangmin Tong,Feifei Zhou,Shibing Wang

International journal of molecular sciences 23: PubMed35008490

2021

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yung-Hung Luo,Yi-Ping Yang,Chian-Shiu Chien,Aliaksandr A Yarmishyn,Afeez Adekunle Ishola,Yueh Chien,Yuh-Min Chen,Ping-Hsing Tsai,Tzu-Wei Lin,Mong-Lien Wang,Shih-Hwa Chiou

Journal of hematology & oncology 14:147 PubMed34526102

2021

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjing Qian,Mingfang Zhao,Ruoyu Wang,Heming Li

Respiratory research 21:210 PubMed32778129

2020

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Cuilan Sun,Weiwei Gao,Jiatao Liu,Hao Cheng,Jiqing Hao

Journal of ethnopharmacology 185:60-7 PubMed26976764

2016

Proteomic analysis allows for identifying targets of Yinchenwuling Powder in hyperlipidemic rats.

Applications

Unspecified application

Species

Rat

Ruomeng Li,Linlin Zhao,Ning Wu,Ruiyi Wang,Xin Cao,Xinjian Qiu,Dongsheng Wang

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-FGL1 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody (AB197357)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGL1 antibody (AB197357)

Western blot - Anti-FGL1 antibody (AB197357)

Western blot - Anti-FGL1 antibody (AB197357)

Key facts

Host species

Clonality

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (8)

Product promise